<DOC>
	<DOCNO>NCT00061945</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose alemtuzumab give together combination chemotherapy see well work treat patient untreated acute lymphoblastic leukemia . Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy also work different way kill cancer cell stop grow . Giving alemtuzumab together combination chemotherapy may better way block cancer growth .</brief_summary>
	<brief_title>Alemtuzumab Combination Chemotherapy Treating Patients With Untreated Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility toxicity profile escalate dos Campath-1H ( alemtuzumab ) give subcutaneously post-remission intensification treatment adult acute lymphoblastic leukemia ( ALL ) . II . To determine disease-free survival ( DFS ) overall survival ( OS ) Campath-1H use post-remission intensification treatment adult ALL . III . To determine whether antibody treatment Campath-1H reduce minimal residual disease state adult ALL . IV . To obtain preliminary descriptive data serum level Campath-1H course IV , module D use limited pharmacokinetic sample phase I II component study . V. To obtain feasibility data addition imatinib Cancer Leukemia Group B ( CALGB ) induction postremission combination chemotherapy patient Philadelphia chromosome positive ( Ph+ ) ALL . OUTLINE : This dose-escalation study alemtuzumab . COURSE 1 ( module A ) : Patients receive allopurinol orally ( PO ) 4 time daily ( QID ) day 1-14 , cyclophosphamide* intravenously ( IV ) 15-30 minute day 1 , daunorubicin hydrochloride IV day 1-3 , vincristine sulfate IV day 1 , 8 , 15 , 22 , dexamethasone PO twice daily ( BID ) day 1-7 15-21 , asparaginase subcutaneously ( SC ) day 5 , 8 , 11 , 15 , 18 , 22 , filgrastim SC day 4-11 . Patients Ph+ also receive imatinib mesylate PO day 15-28 . *Note : Patients = 60 year old receive cyclophosphamide . COURSE 2 ( module B ) : Patients receive methotrexate intrathecally ( IT ) day 1 , cytarabine IV 3 hour day 1-3 , dexamethasone eye drop QID day 1-4 , trimethoprim-sulfamethoxazole PO BID 3 time weekly day 1-29 , cyclophosphamide , asparaginase filgrastim course 1 . Patients Ph+ also receive imatinib mesylate PO day 1-28 . COURSE 3 ( module C ) : Patients receive vincristine sulfate IV day 1 , 15 , 29 , methotrexate IV 3 hour IT day 1 , 15 , 19 , methotrexate PO every 6 hour day 1-2 , 15-16 , 29-30 , mercaptopurine PO day 1-35 , leucovorin calcium IV day 2 , 16 , 30 , leucovorin calcium PO every 6 hour day 3-4 , trimethoprim-sulfamethoxazole PO BID 3 time weekly day 1-43 . Patients Ph+ also receive imatinib mesylate PO day 1-42 . COURSE 4 ( module D ) : Patients receive alemtuzumab SC 3 time weekly 4 week begin acyclovir PO QID 6 month ( continue course 8 ) . - Phase I Cohort 1 : 10 mg - Phase I Cohort 2 : 20 mg - Phase I Cohort 3/Phase II MTD : 30 mg COURSE 5 ( module A ) : Patients repeat course 1 , minus allopurinol . COURSE 6 ( module B ) : Patients repeat course 2 . COURSE 7 ( module C ) : Patients repeat course 3 . COURSE 8 : Patients receive mercaptopurine PO , vincristine sulfate IV day 1 , dexamethasone PO day 1-5 , methotrexate PO day 1 , 8 , 15 , 22 , trimethoprim-sulfamethoxazole PO BID 3 day weekly . Patients Ph+ also receive imatinib mesylate PO day 1-28 . Courses repeat every 28 day 24 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Unequivocal histologic diagnosis precursor B precursor T lymphoblastic leukemia ( World Health Organization [ WHO ] classification ) , L1 L2 ALL acute undifferentiated leukemia ( AUL ) ( FrenchAmericanBritish Cooperative group [ FAB ] Classification ) ; Burkitttype ALL ( FAB L3 , surface immunoglobulin [ SIg ] + ) exclude No prior treatment leukemia three permissible exception : Emergency leukapheresis II . Emergency treatment hyperleukocytosis hydroxyurea III . Cranial radiation therapy ( RT ) central nervous system ( CNS ) leukostasis ( one dose ) All patient must pretreatment bone marrow peripheral blood sample submit central immunophenotyping ; patient express CD52 &gt; = 10 % leukemia blast cell channel eligible receive Campath1H module D , course IV</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>